Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population
- PMID: 33144054
- DOI: 10.1016/j.dld.2020.10.014
Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population
Abstract
Background: A growing body of evidence suggests that Non-alcoholic fatty liver disease (NAFLD) and liver fibrosis are associated with cardiovascular disease (CVD). However, the independent role of liver fibrosis markers in the prediction of CVD in the general population is seldom tested.
Aims: To assess whether a marker of liver fibrosis predicts the first occurrence of a CVD event in a large sample of community-based general population.
Methods: Historical cohort using data from a large health provider that operates a centralized computerized medical record. The level of liver fibrosis was measured by the fibrosis-4 (FIB-4) score, and the association with CVD was adjusted for the European Systematic Coronary Risk Evaluation calculator (SCORE).
Results: The study included 8,511 individuals, 3,292 with inconclusive fibrosis and 195 with advanced fibrosis (FIB-4 ≥ 2.67). People with advanced fibrosis had higher risk for CVD, after adjustment for sociodemographic characteristics, the SCORE, use of statins and aspirin (HR [95%CI], 1.63 [1.29-2.06]). The association persisted in both women and men. Using age-specific cut-offs, there was a dose-response association between inconclusive and advanced fibrosis and CVD (HR [95%CI], 1.15 [1.01-1.31]) and HR [95%CI], 1.60 [1.27-2.01], respectively, P for trend<0.001).
Conclusions: A simple fibrosis score is independently associated with CVD, suggesting that fibrosis markers should be considered in primary-care risk assessment.
Keywords: Cardiovascular; Fibrosis marker; NAFLD; Risk prediction.
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Comment in
-
Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk?Dig Liver Dis. 2021 Mar;53(3):383-384. doi: 10.1016/j.dld.2020.12.123. Epub 2021 Jan 20. Dig Liver Dis. 2021. PMID: 33483258 No abstract available.
-
Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?".Dig Liver Dis. 2021 Mar;53(3):385-386. doi: 10.1016/j.dld.2021.01.014. Epub 2021 Jan 25. Dig Liver Dis. 2021. PMID: 33509738 No abstract available.
Similar articles
-
Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.Am J Physiol Gastrointest Liver Physiol. 2021 Sep 1;321(4):G252-G261. doi: 10.1152/ajpgi.00058.2021. Epub 2021 Jun 16. Am J Physiol Gastrointest Liver Physiol. 2021. PMID: 34132110
-
Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification.J Clin Endocrinol Metab. 2025 Mar 17;110(4):1115-1127. doi: 10.1210/clinem/dgae619. J Clin Endocrinol Metab. 2025. PMID: 39257198 Free PMC article.
-
Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.BMJ Open Diabetes Res Care. 2020 Feb;8(1):e000904. doi: 10.1136/bmjdrc-2019-000904. BMJ Open Diabetes Res Care. 2020. PMID: 32049637 Free PMC article.
-
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3. Epub 2021 Sep 21. Lancet Gastroenterol Hepatol. 2021. PMID: 34555346
-
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.World J Gastroenterol. 2015 Jun 14;21(22):6820-34. doi: 10.3748/wjg.v21.i22.6820. World J Gastroenterol. 2015. PMID: 26078558 Free PMC article. Review.
Cited by
-
Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?J Clin Med. 2021 May 10;10(9):2040. doi: 10.3390/jcm10092040. J Clin Med. 2021. PMID: 34068699 Free PMC article. Review.
-
Liver Fibrosis Scores and Clinical Outcomes in Patients With COVID-19.Front Med (Lausanne). 2022 Apr 8;9:829423. doi: 10.3389/fmed.2022.829423. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35463006 Free PMC article.
-
Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development.Sci Rep. 2024 Oct 7;14(1):23362. doi: 10.1038/s41598-024-74098-w. Sci Rep. 2024. PMID: 39375498 Free PMC article.
-
The association between liver fibrosis score and incident dementia: A nationwide retrospective cohort study.Alzheimers Dement. 2024 Aug;20(8):5385-5397. doi: 10.1002/alz.14033. Epub 2024 Jul 1. Alzheimers Dement. 2024. PMID: 38946688 Free PMC article.
-
Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.Aliment Pharmacol Ther. 2022 Feb;55(3):292-301. doi: 10.1111/apt.16745. Epub 2021 Dec 19. Aliment Pharmacol Ther. 2022. PMID: 34927277 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical